Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the science-heavy language in BeiGene’s oncology disclosures? Each 10-K details dozens of global clinical trials, milestone obligations, and R&D burn-rates that can stretch past 300 pages. Finding when cash runs out—or which trial just moved to Phase III—takes time investors rarely have.
Stock Titan solves that problem. Our AI-powered summaries turn BeiGene SEC filings explained simply, highlighting the exact paragraph that answers questions like “How much did R&D rise this quarter?” or “Which licensing partner triggered a milestone?” Whether you need the BeiGene annual report 10-K simplified, a BeiGene quarterly earnings report 10-Q filing, or BeiGene 8-K material events explained, the platform delivers real-time alerts the moment they hit EDGAR. You’ll also see BeiGene Form 4 insider transactions real-time, complete with context so you understand why an executive sold shares before a data readout.
Dig deeper without getting lost: track BeiGene insider trading Form 4 transactions to spot buying trends, scan BeiGene proxy statement executive compensation to evaluate alignment, and run instant BeiGene earnings report filing analysis to compare pipeline spending quarter-over-quarter. From understanding BeiGene SEC documents with AI to monitoring BeiGene executive stock transactions Form 4, every filing type is covered and linked to the metrics that matter—so you make informed decisions faster.
BeOne Medicines (ONC) – Form 4 insider activity
Chief Financial Officer Aaron Rosenberg reported a mandatory tax-related sale of 1,190 American Depositary Shares (ADS) on 08/01/2025 at $290.47 per ADS, generating roughly $0.35 million in proceeds. Each ADS represents 13 ordinary shares. The disposition was executed automatically to cover withholding taxes triggered by the vesting of a restricted share-unit (RSU) grant. One-quarter of the RSU award vests annually on 31 July through 2028, with accelerated vesting possible upon certain termination events.
No derivative securities were exercised or disposed of in this filing. After the transaction, Rosenberg directly owns 215,332 ordinary shares and 0 ADS, meaning the shares sold equal about 7 % of his reported equity stake. The filing shows continued equity alignment through ongoing RSU vesting, while the share sale itself may be viewed as a routine liquidity event rather than an indicator of fundamental outlook.
BeOne Medicines Ltd. (ONC) – Form 4 filing dated 31-Jul-2025
SVP & General Counsel Henry Chan Lee reported a mandatory tax-related sale of 920 American Depositary Shares (ADS) on 30-Jul-2025 at a weighted-average price of $304.6008. Each ADS equals 13 ordinary shares, so the transaction represents the disposition of roughly 11,960 ordinary shares equivalent.
The ADS were automatically sold to cover withholding taxes upon vesting of a previously granted RSU award that vests 25 % annually on the anniversary of 29-Jul-2022, with possible acceleration on certain termination events. Following the sale, Lee continues to hold 266,474 ordinary shares directly.
- No derivative security activity was reported.
- The filing was executed by attorney-in-fact Qing Nian.
The transaction appears routine and driven by tax-withholding obligations rather than discretionary selling, limiting its market significance.
BeOne Medicines (ONC) filed a routine Form 4 showing Global Head of R&D Lai Wang sold 1,028 American Depositary Shares on 06/23/2025 at $260 each (≈ $0.27 million) to cover tax withholding linked to vested RSUs. After the sale, he still holds 1,023,529 ordinary shares directly and 731,965 indirectly via Wang Holdings LLC—together ≈ 1.76 million shares. The transaction represents under 1 % of his total ownership and is not considered material.
BeOne Medicines (ONC) filed a routine Form 4 reporting a small insider transaction by President & COO Wu Xiaobin.
On 06/23/2025, Wu disposed of 1,363 American Depositary Shares at $260 per ADS (≈$0.35 million) to satisfy mandatory tax-withholding on vested RSUs. Post-sale holdings remain substantial at 1,228,328 ordinary shares plus 16,365 ADSs (4,000 held indirectly by spouse). No other changes to ownership, compensation, or governance were disclosed.
FAQ
What is the current stock price of BeOne Medicines Ltd. (ONC)?
What is the market cap of BeOne Medicines Ltd. (ONC)?
